Matthew Carabasi

2.7k citations

47 papers · 1.7k indexed · 1 hit paper · h-index 15

Hematology top 1%
- Hematopoietic Stem Cell Transplantation 25
- Acute Myeloid Leukemia Research 12
- Multiple Myeloma Research and Treatments 9
Oncology top 5%
- Neutropenia and Cancer Infections 5
Immunology top 5%
- Immune Cell Function and Interaction 14
- T-cell and B-cell Immunology 7
Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment 6
Epidemiology top 5%
- Cytomegalovirus and herpesvirus research 5

Co-authors: Esperanza B. Papadopoulos Alfred P. Gillio Hugo Castro‐Malaspina James W. Young Nancy A. Kernan Stephen Mackinnon Farid Boulad Barrett H. Childs
Cited by: Hematology Oncology Immunology
Journals: New England Journal of Medicine (1 paper)Journal of Clinical Oncology (4 papers)Blood (15 papers)
Partner nations: United States Sweden Canada

In The Last Decade

Matthew Carabasi

41 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Matthew Carabasi

Since Specialization

Citations

This map shows the geographic impact of Matthew Carabasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Carabasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Carabasi more than expected).

Fields of papers citing papers by Matthew Carabasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Carabasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Carabasi. The network helps show where Matthew Carabasi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew Carabasi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew Carabasi Line = papers co-authored together Matthew Carabasi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia Cancers ·Neil Palmisiano,Grace R. Jeschke,Lindsay Wilde,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Dolores Grosso,Thomas R. Klumpp,Ubaldo Martínez,John L. Wagner,Martin Carroll,Alexander E. Perl,Margaret Kasner	2023	0
2	A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation Transplantation and Cellular Therapy ·Dolores Grosso,Benjamin E. Leiby,Lindsay Wilde,Matthew Carabasi,Joanne Filicko-O’Hara,William O’Hara,John L. Wagner,Gina Mateja,Önder Alpdoğan,Adam Binder,Margaret Kasner,Gina Keiffer,Thomas R. Klumpp,Ubaldo Outschoorn Martinez,Neil Palmisiano,Pierluigi Porcu,Usama Gergis,Neal Flomenberg	2022	3
3	Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies Bone Marrow Transplantation ·Xia Bi,Usama Gergis,John L. Wagner,Matthew Carabasi,Joanne Filicko-O’Hara,William O’Hara,Thomas R. Klumpp,Pierluigi Porcu,Neal Flomenberg,Dolores Grosso	2022	3
4	Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes Biology of Blood and Marrow Transplantation ·Dolores Grosso,Matthew Carabasi,Joanne Filicko-O’Hara,John L. Wagner,William O’Hara,Michael Sun,Beth Colombe,Wenyin Shi,Maria Werner‐Wasik,Shannon Rudolph,Önder Alpdoğan,Adam Binder,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,Neil Palmisiano,Lindsay Wilde,Pierluigi Porcu,Usama Gergis,Neal Flomenberg	2020	3
5	COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience Blood ·Lindsay Wilde,Adam Binder,Matthew Carabasi,Joanne Filicko-O’Hara,John L. Wagner,Önder Alpdoğan,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,Neil Palmisiano,Gina Keiffer,Dolores Grosso,Michael Millenson,Amy R. MacKenzie,Allison Zibelli,Neal Flomenberg,Pierluigi Porcu,Usama Gergis	2020	1
6	An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation Transplantation and Cellular Therapy ·Chetan Jeurkar,Benjamin E. Leiby,Joshua Banks,Amy Leader,Shannon Rudolph,Gina Mateja,Shaik Rashid,Matthew Carabasi,Joanne Filicko-O’Hara,William O’Hara,John L. Wagner,Usama Gergis,Neal Flomenberg,Dolores Grosso	2020	4
7	Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters Biology of Blood and Marrow Transplantation ·Jason Chen,Jonathan Pan,Tingting Zhan,Sherilyn A. Tuazon,Neeraj Saini,William O’Hara,Joanne Filicko-O’Hara,Thomas R. Klumpp,Margaret Kasner,Matthew Carabasi,Pierluigi Porcu,John L. Wagner	2019	6
8	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition Investigational New Drugs ·Margaret Kasner,Rosemarie Mick,Grace R. Jeschke,Matthew Carabasi,Joanne Filicko-O’Hara,Neal Flomenberg,Noelle V. Frey,Elizabeth O. Hexner,Selina M. Luger,Alison W. Loren,James K. Mangan,John L. Wagner,Mark A. Weiss,Martin Carroll,Alexander E. Perl	2018	17
9	Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT) Blood ·Jason Chen,Jonathan Pan,John L. Wagner,Michael Sun,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Sameh Gaballa,Margaret Kasner,Thomas R. Klumpp,Neil Palmisiano,Ubaldo Martinez‐Outschoorn,Pierluigi Porcu,Neal Flomenberg,Dolores Grosso	2017	1
10	Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome Bone Marrow Transplantation ·Praveen Ramakrishnan Geethakumari,Benjamin E. Leiby,Rasmi G. Nair,Seyfettin Onder Alpdogan,Matthew Carabasi,Joanne Filicko-O’Hara,Sameh Gaballa,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,Neil Palmisiano,John L. Wagner,Pierluigi Porcu,Neal Flomenberg,Dolores Grosso	2017	3
11	Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization Bone Marrow Transplantation ·Dolores Grosso,Eugene H. Johnson,Beth Colombe,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Sameh Gaballa,Margaret Kasner,Thomas R. Klumpp,Ubaldo Martinez‐Outschoorn,John L. Wagner,Mark A. Weiss,Z Wang,Neal Flomenberg	2017	11
12	A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation Biology of Blood and Marrow Transplantation ·Sameh Gaballa,Neil Palmisiano,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Margaret Kasner,Walter K. Kraft,Benjamin E. Leiby,Ubaldo Martinez‐Outschoorn,William O’Hara,Barbara Pro,Shannon Rudolph,Manish Sharma,John L. Wagner,Mark A. Weiss,Neal Flomenberg,Dolores Grosso	2015	21
13	A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease Biology of Blood and Marrow Transplantation ·Dolores Grosso,Sameh Gaballa,Önder Alpdoğan,Matthew Carabasi,Joanne Filicko-O’Hara,Margaret Kasner,Ubaldo Martinez‐Outschoorn,John L. Wagner,William O’Hara,Shannon Rudolph,Inna Chervoneva,Beth Colombe,Patricia Cornett Farley,Phyllis Flomenberg,Barbara Pro,Manish Sharma,Wenyin Shi,Mark A. Weiss,Neal Flomenberg	2014	31
14	Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? Journal of Clinical Oncology ·John Horan,Brent R. Logan,Afiba Manza‐A. Agovi,Hillard M. Lazarus,Andrea A. Bacigalupo,Karen K. Ballen,Christopher Bredeson,Matthew Carabasi,Vikas Gupta,Gregory A. Hale,H. Jean Khoury,Mark Juckett,Mark R. Litzow,Rodrigo Martino,Philip L. McCarthy,Franklin O. Smith,J. Douglas Rizzo,Marcelo C. Pasquini	2011	133
15	Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen Biology of Blood and Marrow Transplantation ·Charu Aggarwal,Sameer Gupta,William P. Vaughan,Gene Saylors,Donna Salzman,R. Katz,Amy G. Nance,Arabella B. Tilden,Matthew Carabasi	2006	40
16	Clinical Protocol: A Phase I-II Trial to Examine the Toxicity of CMV- and EBV-Specific Cytotoxic T Lymphocytes When Used for Prophylaxis against EBV and CMV Disease in Recipients of CD34-Selected/T Cell-Depleted Stem Cell Transplants Human Gene Therapy ·KENNETH G. LUCAS,Qingsong Sun,Robert L. Burton,Arabella B. Tilden,William P. Vaughan,Matthew Carabasi,Donna Salzman,Alan M. Ship	2000	38
17	A Novel Gene Therapy Strategy for Elimination of Prostate Carcinoma Cells from Human Bone Marrow Human Gene Therapy ·Myung‐Hee Kim,M. Wright,Jessy S. Deshane,Mary Ann Accavitti,Arabella B. Tilden,Mansoor N. Saleh,William P. Vaughan,Matthew Carabasi,Miriam D. Rogers,Richard D. Hockett,William E. Grizzle,David T. Curiel	1997	25
18	Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantationbreakdown → New England Journal of Medicine ·Esperanza B. Papadopoulos,Marc Ladanyi,David Emanuel,Stephen Mackinnon,Farid Boulad,Matthew Carabasi,Hugo Castro‐Malaspina,Barrett H. Childs,Alfred P. Gillio,Trudy N. Small,James W. Young,Nancy A. Kernan,Richard J. O’Reilly	1994	809
19	New technology for the depletion of T cells from soybean lectin agglutinated, HLA-matched bone marrow grafts for leukemia: initial laboratory and clinical results. PubMed ·N H Collins,Matthew Carabasi,Sharon A. Bleau,C Jagiello,James W. Young,Hugo Castro‐Malaspina,Neal Flomenberg,Esperanza B. Papadopoulos,David Emanuel,Alfred P. Gillio	1992	7
20	Activation of peripheral CD8⁺ T lymphocytes via CD28 plus CD2: Evidence for IL‐2 gene transcription mediated by CD28 activation Tissue Antigens ·Matthew Carabasi,James P. Di Santo,Soo Young Yang,Bo Dupont	1991	3

About Matthew Carabasi

Matthew Carabasi is a scholar working on Hematology, Transplantation and Immunology, having authored 47 papers that have together received 1.7k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (25 papers), Immune Cell Function and Interaction (14 papers), Acute Myeloid Leukemia Research (12 papers), Multiple Myeloma Research and Treatments (9 papers), T-cell and B-cell Immunology (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Neutropenia and Cancer Infections (5 papers) and Cytomegalovirus and herpesvirus research (5 papers). The work is most often cited by research in Hematology (682 citations), Oncology (910 citations) and Immunology (549 citations). Matthew Carabasi has collaborated with scholars based in United States, Sweden and Canada. Frequent co-authors include Esperanza B. Papadopoulos, Alfred P. Gillio, Hugo Castro‐Malaspina, James W. Young, Nancy A. Kernan, Stephen Mackinnon, Farid Boulad, Barrett H. Childs, David Emanuel and Marc Ladanyi. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact